RxDoctor Payments DataLook up a doctor →

Kimberly Felts

Family · Lebanon, TNNPI 1225070337

Payments from drug & device makers

$64,425in general payments, 2019–2025

Across 716 payments — averaging $89.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$23K
  • Gilead$22K
  • QOL Medical, LLC$8K
  • AbbVie$3K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • plus $5K from 35 others

What the payments were for

  • Consulting fees$7501%
  • Speaking & faculty fees$39,37361%
  • Travel & lodging$10,78117%
  • Food & beverage$13,15520%
  • Education$3321%
  • Other$340%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,425 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$32,185
Medicare patients
228
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SucraidSacrosidase41$579,656
ZenpepLipase/Protease/Amylase36$139,019
CreonLipase/Protease/Amylase22$123,653
XifaxanRifaximin13$42,212
LinzessLinaclotide62$40,847
VoqueznaVonoprazan Fumarate13$7,984
Pantoprazole Sodium227$3,373
Colestipol Hcl48$3,243
Mesalamine ErMesalamine27$2,645
Omeprazole165$2,550
Famotidine218$2,448
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C13$1,844
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates29$1,684
Sucralfate48$1,472
Budesonide DrBudesonide13$1,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
QOL Medical, LLCSucraid$8,080$579,65641 claims
AbbVieCreon, Linzess$3,451$164,50084 claims
Aimmune Therapeutics, Inc.Zenpep$45$139,01936 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$1,315$44,05626 claims
Phathom Pharmaceuticals, Inc.Voquezna$252$7,98413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Lebanon

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →